<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909064</url>
  </required_header>
  <id_info>
    <org_study_id>200816251-2</org_study_id>
    <secondary_id>GSK576428</secondary_id>
    <nct_id>NCT00909064</nct_id>
  </id_info>
  <brief_title>The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty</brief_title>
  <official_title>The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <brief_summary>
    <textblock>
      The investigators hypothesize that Arixtra patients will be less likely to experience wound
      infection than patients who have received low-molecular weight heparin, coumadin or aspirin
      with mechanical compression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days until a dry wound</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Number of days in hospital. 2.Incidence of wound infection.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">91</enrollment>
  <condition>Total Knee Replacement</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux Sodium (Arixtra)</intervention_name>
    <description>2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.</description>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All primary unilateral TKA and THA cases will be included.

        Exclusion Criteria:

          -  Patients less than 50 kg, Patients with CrCl&lt;30ml/min. Revision and bilateral
             procedures will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E. DiCesare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anto Fritz, M D</last_name>
    <phone>925 785 0826</phone>
    <email>atfritz@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>U C Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anto Fritz, MD</last_name>
      <phone>925-785-0826</phone>
      <email>atfritz@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 26, 2009</lastchanged_date>
  <firstreceived_date>May 22, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Dr. Paul E. Di Cesare</name_title>
    <organization>University of California Davis Health System</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
